Compare Danaher Corporation (DHR) vs Newmont Corporation (NEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Newmont Corporation — how do they compare? Danaher Corporation trades at $197.72 (market cap $140.88B), while Newmont Corporation trades at $94 (market cap $101.15B). The key difference: Danaher Corporation is the larger of the two by market cap, and Newmont Corporation pays the higher dividend (1.1%). Which is the better fit depends on your goals.
| DHR | NEM | |
|---|---|---|
Market Cap | $140.88B | $101.15B |
Sector | Health | Basic Materials |
52-Week High | $242.05 | $131.95 |
52-Week Low | $161.91 | $57.35 |
Enterprise Value | $153.66B | $97.90B |
Dividend Yield | 0.8% | 1.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $199.05, showing minimal daily change, with a bullish technical signal supported by moving averages. The company maintains strong profitability with a 58.94% gross margin and has beaten earnings estimates for the last three quarters. Recent news highlights the acquisition of Masimo and new product launches in its SCIEX division, indicating growth initiatives. Cash flow improved in 2025 to a net inflow of $2.54 billion, though revenue growth remains modest.
The outlook is positive with a consensus price target of $211.33, representing a 6% upside, and 69% of analysts rate it a buy. Risks include slowing revenue growth, high valuation multiples, and integration challenges from acquisitions. The stock offers a dividend yield supported by stable cash flows, but investors should monitor competitive pressures in the life sciences sector.
Newmont (NEM) trades at $93.10, down 2.3% over the past day amid a bearish technical signal. The stock shows strong fundamentals with a P/E of 12.08, net income margin of 33.87%, and three consecutive quarterly earnings beats. Recent news highlights Wall Street's positive valuation view despite near-term cost pressures. Cash flow trends are robust, with operating cash flow rising to $10.33 billion in 2025.
Outlook remains favorable given analyst consensus of a $140.11 price target and 75% buy ratings. Key risks include higher unit costs impacting 2026 margins and gold price volatility. The stock offers value with solid profitability and growth, though investors should monitor cost management and gold market dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →
